Jazz Pharmaceuticals (JAZZ) Cash & Current Investments (2010 - 2026)

Jazz Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 0.95% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (down 0.95% YoY), while the FY2025 annual figure was $1.4 billion, down 42.31% from the prior year.
• Cash & Current Investments was $1.8 billion for Q1 2026 at Jazz Pharmaceuticals, up from $1.4 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.4 billion in Q4 2024 to a low of $490.8 million in Q1 2022.
• Historically, Cash & Current Investments has averaged $1.4 billion across 5 years, with a median of $1.3 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments slumped 76.6% in 2022, then surged 137.94% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $881.5 million in 2022, then surged by 70.88% to $1.5 billion in 2023, then jumped by 60.18% to $2.4 billion in 2024, then sank by 42.31% to $1.4 billion in 2025, then surged by 32.5% to $1.8 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.8 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.